S
KYMR icon

SignatureFD’s Kymera Therapeutics KYMR Stock Holding History

SignatureFD’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.1K Buy
167
+5
+3% +$430 ﹤0.01% 2364
2026
Q1 		$13.5K Buy
162
+22
+16% +$1.74K ﹤0.01% 2381
2025
Q4 		$10.9K Hold
140
– – ﹤0.01% 2394
2025
Q3 		$7.92K Hold
140
– – ﹤0.01% 2493
2025
Q2 		$6.11K Buy
140
+65
+87% +$2.24K ﹤0.01% 2533
2025
Q1 		$2.05K Buy
75
+16
+27% +$583 ﹤0.01% 2863
2024
Q4 		$2.37K Hold
59
– – ﹤0.01% 2820
2024
Q3 		$2.79K Hold
59
– – ﹤0.01% 2735
2024
Q2 		$1.76K Hold
59
– – ﹤0.01% 2790
2024
Q1 		$2.37K Hold
59
– – ﹤0.01% 2759
2023
Q4 		$1.5K Buy
+59
New +$1.05K ﹤0.01% 2833
2023
Q3 		– Sell
-31
Closed -$713 – 3258
2023
Q2 		$713 Buy
31
+12
+63% +$344 ﹤0.01% 3031
2023
Q1 		$563 Buy
+19
New +$613 ﹤0.01% 3083
2022
Q1 		– Sell
-16
Closed -$1K – 3239
2021
Q4 		$1K Buy
+16
New +$932 ﹤0.01% 2943
2021
Q3 		– Sell
-16
Closed -$1K – 3135
2021
Q2 		$1K Buy
+16
New +$695 ﹤0.01% 2755

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

SignatureFD's KYMR Position: Q2 2026 in Review

SignatureFD increased its Kymera Therapeutics (KYMR) stake by 3.1% in Q2 2026, buying an estimated $430 and bringing the position to 167 shares worth $19.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2364.

SignatureFD first reported a position in KYMR in Q2 2021 and has held it in 15 quarters since. 276 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • SignatureFD held 167 shares of Kymera Therapeutics worth $19.1K as of Q2 2026.
  • SignatureFD bought 5 Kymera Therapeutics shares in Q2 2026, an estimated $430.
  • Kymera Therapeutics made up ﹤0.01% of SignatureFD's portfolio in Q2 2026, its #2364 holding.
  • SignatureFD first reported a position in Kymera Therapeutics in Q2 2021 and has held it in 15 quarters since.
  • 276 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on SignatureFD's 13F filing for Q2 2026, filed 24 Jul 2026.